Mood-stimulating drugs used primarily in the treatment of affective disorders and related conditions. Several MONOAMINE OXIDASE INHIBITORS are useful as antidepressants apparently as a long-term consequence of their modulation of catecholamine levels. The tricyclic compounds useful as antidepressive agents (ANTIDEPRESSIVE AGENTS, TRICYCLIC) also appear to act through brain catecholamine systems. A third group (ANTIDEPRESSIVE AGENTS, SECOND-GENERATION) is a diverse group of drugs including some that act specifically on serotonergic systems.
A structurally and mechanistically diverse group of drugs that are not tricyclics or monoamine oxidase inhibitors. The most clinically important appear to act selectively on serotonergic systems, especially by inhibiting serotonin reuptake.
Substances that contain a fused three-ring moiety and are used in the treatment of depression. These drugs block the uptake of norepinephrine and serotonin into axon terminals and may block some subtypes of serotonin, adrenergic, and histamine receptors. However the mechanism of their antidepressant effects is not clear because the therapeutic effects usually take weeks to develop and may reflect compensatory changes in the central nervous system.
A tetracyclic compound with antidepressant effects. It may cause drowsiness and hematological problems. Its mechanism of therapeutic action is not well understood, although it apparently blocks alpha-adrenergic, histamine H1, and some types of serotonin receptors.
An activity in which the body is propelled through water by specific movement of the arms and/or the legs. Swimming as propulsion through water by the movement of limbs, tail, or fins of animals is often studied as a form of PHYSICAL EXERTION or endurance.
The first highly specific serotonin uptake inhibitor. It is used as an antidepressant and often has a more acceptable side-effects profile than traditional antidepressants.
Depressive states usually of moderate intensity in contrast with major depression present in neurotic and psychotic disorders.
An affective disorder manifested by either a dysphoric mood or loss of interest or pleasure in usual activities. The mood disturbance is prominent and relatively persistent.
The observable response an animal makes to any situation.

Various forms of chemically induced liver injury and their detection by diagnostic procedures. (1/3228)

A large number of chemical agents, administered for therapeutic or diagnostic purposes, can produce various types of hepatic injury by several mechanisms. Some agents are intrinsically hepatotoxic, and others produce hepatic injury only in the rare, uniquely susceptible individual. Idiosyncrasy of the host is the mechanism for most types of drug-induced hepatic injury. It may reflect allergy to the drug or a metabolic aberation of the host permitting the accumulation of hepatotoxic metabolites. The syndromes of hepatic disease produced by drugs have been classified hepatocellular, hepatocanalicular, mixed and canalicular. Measurement of serum enzyme activities has provided a powerful tool for studies of hepatotoxicity. Their measurement requires awareness of relative specificity, knowledge of the mechanisms involved, and knowledge of the relationship between known hepatotoxic states and elevated enzyme activities.  (+info)

Psychotropic drug use among women. (2/3228)

The consistent 2:1 ratio of women to men in the receipt of prescriptions for psychotropic drugs is reflected in the higher rates for women of neurotic illness, symptoms of both physical and mental discomfort, and help-seeking and drug-taking behaviour. Physicians' perceptions of the problems presented by their male and female patients influence their prescribing of these drugs. Recent statistics in Ontario indicate that greater use of physicians' services by women is an inadequate explanation of the higher rate of prescribing of psychotropic drugs to women. A longitudinal study of a large insured population in Ontario showed that almost twice the proportion of females, compared with males, received a prescription for psychotropic drugs in 1970-71 and in 1973-74, a higher proportion of females received multiple prescriptions for each drug class, and males were more likely than females to have received only one prescription in a year.  (+info)

Alternative insurance arrangements and the treatment of depression: what are the facts? (3/3228)

Using insurance claims data from nine large self-insured employers offering 26 alternative health benefit plans, we examine empirically how the composition and utilization for the treatment of depression vary under alternative organizational forms of insurance (indemnity, preferred provider organization networks, and mental health carve-outs), and variations in patient cost-sharing (copayments for psychotherapy and for prescription drugs). Although total outpatient mental health and substance abuse expenditures per treated individual do not vary significantly across insurance forms, the depressed outpatient is more likely to receive anti-depressant drug medications is preferred provider organizations and carve-outs than when covered by indemnity insurance. Those individuals facing higher copayments for psychotherapy are more likely to receive anti-depressant drug medications. For those receiving treatment, increases in prescription drug copayments tend to increase the share of anti-depressant drug medication costs accounted for by the newest (and more costly) generation of drugs, the selective serotonin reuptake inhibitors.  (+info)

Outpatient antidepressant utilization in a Dutch sick fund. (4/3228)

OBJECTIVE: To identify quality improvement opportunities in the management of depression by evaluating patterns of antidepressant use and concurrent use of anxiolytics or sedative/hypnotics among patients who initiated therapy with amitriptyline, fluoxetine, fluvoxamine, or paroxetine. DESIGN: A longitudinal, retrospective study using electronic prescription data from a Dutch sick fund, ZAO Zorgverzekeringen. PATIENTS AND METHODS: The study patients (n = 2,554) initiated therapy between October 1, 1994 and December 31, 1995. Follow-up periods were 6 months (antidepressant use) and 60 days (concurrent anxiolytic and sedative/hypnotic use). RESULTS: The three key findings were as follows: (1) the majority of patients received less than 4 months of therapy (more common for patients receiving amitriptyline); (2) the average daily doses for initial prescriptions for all four study drugs were below the recommended therapeutic minimums for depression (overall and final amitriptyline doses also were consistently low); and (3) the incidence of concurrent anxiolytic and sedative/hypnotic use during days 2-60 after antidepressant therapy initiation was 18.2%. CONCLUSION: The study suggests that patients in this Dutch sick fund were not likely to receive either adequate antidepressant doses or adequate durations of therapy relative to Dutch guidelines for the treatment of depression. These findings are consistent with findings in other Dutch, European, and US studies and may present opportunities for quality improvement.  (+info)

Amitriptyline and procainamide inhibition of cocaine and cocaethylene degradation in human serum in vitro. (5/3228)

Amitriptyline (AMI) and procainamide (PA) have been reported to inhibit the activity of human plasma butyrylcholinesterase, an enzyme important in the metabolic degradation of cocaine (COC) and its ethyl analogue cocaethylene (CE). Because both AMI and PA may be used in the treatment of COC intoxication and abuse, the effect of high pharmacological concentrations of these compounds on the degradation of COC and CE in pooled human serum was studied. AMI (1.8 micromol/L) modestly inhibited the degradation of COC by 4.2% and of CE by 4.0%. PA (42.5 micromol/L) profoundly inhibited degradation of COC by 42.7% and of CE by 47.2%. In contrast, lithium carbonate (1 mmol/L, control) showed no inhibition of degradation of either COC or CE. These results suggest that AMI and PA may prolong the half-life of COC and CE in human serum.  (+info)

Drug-induced heart failure. (6/3228)

Heart failure is a clinical syndrome that is predominantly caused by cardiovascular disorders such as coronary heart disease and hypertension. However, several classes of drugs may induce heart failure in patients without concurrent cardiovascular disease or may precipitate the occurrence of heart failure in patients with preexisting left ventricular impairment. We reviewed the literature on drug-induced heart failure, using the MEDLINE database and lateral references. Successively, we discuss the potential role in the occurrence of heart failure of cytostatics, immunomodulating drugs, antidepressants, calcium channel blocking agents, nonsteroidal anti-inflammatory drugs, antiarrhythmics, beta-adrenoceptor blocking agents, anesthetics and some miscellaneous agents. Drug-induced heart failure may play a role in only a minority of the patients presenting with heart failure. Nevertheless, drug-induced heart failure should be regarded as a potentially preventable cause of heart failure, although sometimes other priorities do not offer therapeutic alternatives (e.g., anthracycline-induced cardiomyopathy). The awareness of clinicians of potential adverse effects on cardiac performance by several classes of drugs, particularly in patients with preexisting ventricular dysfunction, may contribute to timely diagnosis and prevention of drug-induced heart failure.  (+info)

The effects of detection and treatment on the outcome of major depression in primary care: a naturalistic study in 15 cities. (7/3228)

BACKGROUND: This study reports the responses of patients with confirmed depressive illnesses to different treatments in the WHO Mental Disorders in General Health Care study, conducted in 15 cities around the world. AIM: To discover how depressions recognized by the doctor compare with unrecognized depressions, both in terms of the initial illnesses and their outcomes, and to compare the outcomes of those depressions treated with antidepressants with those treated with daytime sedatives. METHOD: The design of the study was naturalistic, in that physicians were free to treat patients however they wished. Patients with confirmed depressive illnesses were assigned to four groups: treatment with an antidepressant; treatment with a daytime sedative (usually a benzodiazepine); patients recognized as having depression by the physician but were not offered drug treatment; and patients unrecognized as having depression by their physician. RESULTS: Both groups receiving drugs had illnesses of equal severity, were demographically similar to one another, and had similar previous histories of depression. Those receiving antidepressants had significantly fewer overall symptoms and fewer suicidal thoughts than those treated with sedatives. By the end of one year, differences between the groups had disappeared: patients not given drugs had milder illnesses but did significantly better than those receiving drugs, both in terms of symptoms lost and their diagnostic status. Unrecognized depressions were less severe than recognized depressions, and had a similar course over the year. CONCLUSIONS: Patients receiving antidepressants were better in terms of overall symptoms and suicidal thoughts than those treated with sedatives at three months, but this advantage does not persist. Depression emerges as a chronic disorder at one-year follow-up--about 60% of those treated with drugs, and 50% of the milder depressions, still meet criteria for caseness. The study does not support the view that failure to recognize depression has serious adverse consequences, but, in view of the poor prognosis of depression, measures to improve compliance with treatment would appear to be indicated.  (+info)

Depressive state with anxiety in repeated cold-stressed mice in forced swimming tests. (8/3228)

The effects of various types of stress and drugs were studied to assess mouse performance in forced swimming tests, following characterization of SART (specific alternation of rhythm in environmental temperature) stress. Immobility time in the test decreased in mice subjected to SART, acute cold and restraint stress. No change was noted due to chronic cold stress or repeated fasting. The shortened time did not recover even 24 hr after the end of SART and chronic restraint stress. The time in SART-stressed mice finally recovered at 5-7 days. Shortening of immobility time in SART-stressed mice was inhibited by diazepam and repeated imipramine but not by lithium carbonate. In chronic restraint-stressed mice, this time was inhibited by repeated lithium carbonate but not diazepam or imipramine. SART stress would thus appear related to anxiety and depression and may be useful for detecting new types of antidepressants.  (+info)

Antidepressive agents are a class of medications used to treat various forms of depression and anxiety disorders. They act on neurotransmitters, the chemical messengers in the brain, to restore the balance that has been disrupted by mental illness. The most commonly prescribed types of antidepressants include selective serotonin reuptake inhibitors (SSRIs), serotonin and norepinephrine reuptake inhibitors (SNRIs), tricyclic antidepressants (TCAs), and monoamine oxidase inhibitors (MAOIs). These medications can help alleviate symptoms such as low mood, loss of interest in activities, changes in appetite and sleep patterns, fatigue, difficulty concentrating, and thoughts of death or suicide. It is important to note that antidepressants may take several weeks to reach their full effectiveness and may cause side effects, so it is essential to work closely with a healthcare provider to find the right medication and dosage.

Second-generation antidepressants (SGAs) are a class of medications used primarily for the treatment of depression, although they are also used for other psychiatric and medical conditions. They are called "second-generation" because they were developed after the first generation of antidepressants, which include tricyclic antidepressants (TCAs) and monoamine oxidase inhibitors (MAOIs).

SGAs are also known as atypical antidepressants or novel antidepressants. They work by affecting the levels of neurotransmitters in the brain, such as serotonin, norepinephrine, and dopamine. However, they have a different chemical structure and mechanism of action than first-generation antidepressants.

Some examples of second-generation antidepressants include:

* Selective serotonin reuptake inhibitors (SSRIs) such as fluoxetine (Prozac), sertraline (Zoloft), and citalopram (Celexa)
* Serotonin-norepinephrine reuptake inhibitors (SNRIs) such as venlafaxine (Effexor) and duloxetine (Cymbalta)
* Norepinephrine and dopamine reuptake inhibitors (NDRIs) such as bupropion (Wellbutrin)
* Atypical antidepressants such as mirtazapine (Remeron), trazodone, and vortioxetine (Brintellix)

SGAs are generally considered to have a more favorable side effect profile than first-generation antidepressants. They are less likely to cause anticholinergic effects such as dry mouth, constipation, and blurred vision, and they are less likely to cause cardiac conduction abnormalities or orthostatic hypotension. However, SGAs may still cause side effects such as nausea, insomnia, sexual dysfunction, and weight gain.

It's important to note that the choice of antidepressant medication should be individualized based on the patient's specific symptoms, medical history, and other factors. It may take some trial and error to find the most effective and well-tolerated medication for a given patient.

Tricyclic antidepressants (TCAs) are a class of medications that were commonly used to treat depression. The name "tricyclic" comes from the chemical structure of these drugs, which contain three rings in their molecular makeup. TCAs were first developed in the 1950s and remained a popular choice for treating depression until the introduction of selective serotonin reuptake inhibitors (SSRIs) in the late 1980s.

TCAs work by increasing the levels of neurotransmitters, such as serotonin and norepinephrine, in the brain. Neurotransmitters are chemical messengers that transmit signals between nerve cells. By increasing the levels of these neurotransmitters, TCAs can help to improve mood and alleviate symptoms of depression.

Some common examples of tricyclic antidepressants include amitriptyline, imipramine, and nortriptyline. While TCAs are effective in treating depression, they can have significant side effects, including dry mouth, blurred vision, constipation, and drowsiness. In addition, TCAs can be dangerous in overdose and may increase the risk of suicide in some individuals. As a result, they are typically used as a last resort when other treatments have failed.

Overall, tricyclic antidepressants are a class of medications that were commonly used to treat depression but have largely been replaced by newer drugs due to their side effects and potential risks.

Mianserin is a tetracyclic antidepressant (TCA) that is primarily used to treat major depressive disorders. It functions by inhibiting the reuptake of neurotransmitters such as serotonin and noradrenaline, thereby increasing their availability in the brain and helping to alleviate symptoms of depression.

Mianserin also has additional properties, including antihistamine and anti-cholinergic effects, which can help reduce some side effects commonly associated with other antidepressants, such as insomnia and agitation. However, these same properties can also lead to side effects such as drowsiness, dry mouth, and orthostatic hypotension (a drop in blood pressure upon standing).

It's important to note that mianserin is not commonly prescribed due to its narrow therapeutic index and the risk of serious side effects, including agranulocytosis (a severe decrease in white blood cells), which can increase the risk of infection. As with any medication, it should only be taken under the close supervision of a healthcare provider.

I'm sorry for any confusion, but "swimming" is not typically considered a medical term. It refers to the act of moving through water using your arms and legs in a rhythmic pattern, often as a form of exercise, recreation, or competition. However, if you're referring to a medical condition related to swimming, such as "swimmer's ear" (otitis externa), I would be happy to provide a definition for that.

Swimmer's ear is a type of outer ear infection caused by water remaining in the ear after swimming or bathing, creating a moist environment that can lead to bacterial growth. It can also be caused by scratching or damaging the lining of the ear canal through the use of cotton swabs or other objects. Symptoms may include itching, redness, pain, and sometimes discharge from the ear. If left untreated, swimmer's ear can lead to more serious complications, such as hearing loss or damage to the inner ear.

Fluoxetine is a selective serotonin reuptake inhibitor (SSRI) medication that is primarily used to treat major depressive disorder, obsessive-compulsive disorder, bulimia nervosa, panic disorder, and premenstrual dysphoric disorder. It works by increasing the levels of serotonin, a neurotransmitter in the brain that helps maintain mental balance.

Fluoxetine is available under the brand name Prozac and is also available as a generic medication. It comes in various forms, including capsules, tablets, delayed-release capsules, and liquid solution. The typical starting dose for adults with depression is 20 mg per day, but the dosage may be adjusted based on individual patient needs and response to treatment.

Fluoxetine has a relatively long half-life, which means it stays in the body for an extended period of time. This can be beneficial for patients who may have difficulty remembering to take their medication daily, as they may only need to take it once or twice a week. However, it also means that it may take several weeks for the full effects of the medication to become apparent.

As with any medication, fluoxetine can cause side effects, including nausea, dry mouth, sleepiness, insomnia, dizziness, and headache. In some cases, it may also increase the risk of suicidal thoughts or behavior in children, adolescents, and young adults, particularly during the initial stages of treatment. It is important for patients to discuss any concerns about side effects with their healthcare provider.

Depression is a mood disorder that is characterized by persistent feelings of sadness, hopelessness, and loss of interest in activities. It can also cause significant changes in sleep, appetite, energy level, concentration, and behavior. Depression can interfere with daily life and normal functioning, and it can increase the risk of suicide and other mental health disorders. The exact cause of depression is not known, but it is believed to be related to a combination of genetic, biological, environmental, and psychological factors. There are several types of depression, including major depressive disorder, persistent depressive disorder, postpartum depression, and seasonal affective disorder. Treatment for depression typically involves a combination of medication and psychotherapy.

A depressive disorder is a mental health condition characterized by persistent feelings of sadness, hopelessness, and loss of interest or pleasure in activities. It can also include changes in sleep, appetite, energy levels, concentration, and self-esteem, as well as thoughts of death or suicide. Depressive disorders can vary in severity and duration, with some people experiencing mild and occasional symptoms, while others may have severe and chronic symptoms that interfere with their ability to function in daily life.

There are several types of depressive disorders, including major depressive disorder (MDD), persistent depressive disorder (PDD), and postpartum depression. MDD is characterized by symptoms that interfere significantly with a person's ability to function and last for at least two weeks, while PDD involves chronic low-grade depression that lasts for two years or more. Postpartum depression occurs in women after childbirth and can range from mild to severe.

Depressive disorders are thought to be caused by a combination of genetic, biological, environmental, and psychological factors. Treatment typically involves a combination of medication, psychotherapy (talk therapy), and lifestyle changes.

'Animal behavior' refers to the actions or responses of animals to various stimuli, including their interactions with the environment and other individuals. It is the study of the actions of animals, whether they are instinctual, learned, or a combination of both. Animal behavior includes communication, mating, foraging, predator avoidance, and social organization, among other things. The scientific study of animal behavior is called ethology. This field seeks to understand the evolutionary basis for behaviors as well as their physiological and psychological mechanisms.

Lingjaerde O (November 1971). "[Imiprex "Dumex" (imipramine oxide). A new tricyclic antidepressive agent]". Tidsskrift for den ... preliminary investigation of a new antidepressive drug". The American Journal of Psychiatry. 120 (3): 277-8. doi:10.1176/ajp. ...
"Sertraline versus other antidepressive agents for depression". The Cochrane Database of Systematic Reviews (4): CD006117. doi: ... While imprecise, comparison of the results of trials of sertraline with separate trials of other anti-panic agents ( ... Central Nervous System Agents in Medicinal Chemistry. 9 (3): 197-204. doi:10.2174/1871524910909030197. PMID 20021354. Sprouse J ...
"Mirtazapine versus other antidepressive agents for depression". Cochrane Database of Systematic Reviews (12): CD006528. doi: ... Other agents impacting the central nervous system in sufficient or toxic doses Quantifying sleepiness requires a careful ...
"Milnacipran versus other antidepressive agents for depression". The Cochrane Database of Systematic Reviews. 8 (3): CD006529. ... acceptability and tolerability when comparing milnacipran with other antidepressant agents. However, compared with TCAs, ...
"Citalopram versus other anti-depressive agents for depression". The Cochrane Database of Systematic Reviews. 7 (7): CD006534. ... Like other serotonergic agents, SNRIs have the potential to cause serotonin syndrome, a potentially fatal systemic response to ... Overdose of an SSRI or concomitant use with another agent that causes increased levels of serotonin can result in serotonin ...
"Agomelatine versus other antidepressive agents for major depression". The Cochrane Database of Systematic Reviews (12): ...
"Fluvoxamine versus other anti-depressive agents for depression". The Cochrane Database of Systematic Reviews (3): CD006114. doi ... Paclitaxel (Px) is a chemotherapeutic agent for the treatment of various types of cancer. Here, fluvoxamine has been ... Silver H (2001). "Fluvoxamine as an adjunctive agent in schizophrenia". CNS Drug Reviews. 7 (3): 283-304. doi:10.1111/j.1527- ... to keep blood-levels of the two agents within acceptable levels and avoid serotonin-toxicity. Even-greater caution is needed ...
"Agomelatine versus other antidepressive agents for major depression". The Cochrane Database of Systematic Reviews (12): ... "Agomelatine versus other antidepressive agents for major depression". The Cochrane Database of Systematic Reviews (12): ...
Cochrane Common Mental Disorders Group) (July 2023). "Brexpiprazole versus placebo or other antidepressive agents for treating ... They are still used only rarely, although newer and better-tolerated agents of this class have been developed. The safety ... Therapies associated with depression include interferons, beta-blockers, isotretinoin, contraceptives, cardiac agents, ... A meta-analysis of studies of newer agents". Biological Psychiatry. 62 (11): 1217-27. doi:10.1016/j.biopsych.2007.03.027. PMID ...
Galbaud du Fort G (1988). "[Hematologic toxicity of antidepressive agents]" [Hematologic Toxicity of Antidepressive Agents]. ... a new group of antidepressive psycholeptic drugs]". Arzneimittel-Forschung. 21 (7): 1045. PMID 5109496. GB 1164192, " ...
... hydrochloride (Lu 19-005) is an antidepressive agent and non-selective monoamine transporter inhibitor that blocks ...
... a new antidepressive agent, in rats and dogs". Drug Metabolism and Disposition. 9 (3): 233-9. PMID 6113932. Depin JC, Betbeder- ... Norepinephrine reuptake inhibitor David J. Triggle (1997). Dictionary of pharmacological agents. London: Chapman & Hall. ISBN 0 ...
Second-Generation+Antidepressive+Agents at the U.S. National Library of Medicine Medical Subject Headings (MeSH) Diagrams at ...
Tricyclic+Antidepressive+Agents at the U.S. National Library of Medicine Medical Subject Headings (MeSH) (All articles with ... having been replaced by more effective agents with fewer side effects such as atomoxetine (Strattera, Tomoxetin) and stimulants ...
... [Archived]: The Merck Index". Levy J, Michel-Ber E (1966). "[Relations between the antidepressive effects of ... Ganellin, C. R.; Triggle, David J. (21 November 1996). Dictionary of pharmacological agents - Google Books. ISBN 9780412466304 ...
Pirandamine Lippmann W, Pugsley TA (May 1976). "The effects of tandamine, a new potential antidepressant agent, on biogenic ... a potential antidepressive drug". Psychopharmacology. 52 (1): 73-77. doi:10.1007/BF00426603. PMID 403562. S2CID 23960347. ...
Ergoline-derived agents, bromocriptine and cabergoline are mostly used in treatment. Research shows that these agents reduce ... further research is crucial to establish the anti-depressive effects of dopamine agonists in treating depressive symptoms and ... Dopamine agonists are divided into two subgroups or drug classes, first-generation and newer agents. Ergoline derived agonists ... dopamine reuptake inhibitors and dopamine releasing agents. These are not considered dopamine agonists, since they have no ...
... antidepressive agents MeSH D27.505.954.427.700.122.050 - antidepressive agents, second-generation MeSH D27.505.954.427.700.122. ... antiviral agents MeSH D27.505.954.122.388.077 - anti-retroviral agents MeSH D27.505.954.122.388.077.088 - anti-hiv agents MeSH ... tocolytic agents MeSH D27.505.954.016 - anti-allergic agents MeSH D27.505.954.122 - anti-infective agents MeSH D27.505.954.122. ... tranquilizing agents MeSH D27.505.696.277.950.015 - anti-anxiety agents MeSH D27.505.696.277.950.025 - antimanic agents MeSH ...
Hayes AG, Chang T (January 1983). "Determination of indeloxazine, a new antidepressant agent, in human plasma by gas-liquid ... and its derivatives with potential cerebral-activating and antidepressive properties". Chemical & Pharmaceutical Bulletin. 33 ( ... Indeloxazine acts as a serotonin releasing agent, norepinephrine reuptake inhibitor, and NMDA receptor antagonist. It has been ... ISBN 978-3-88763-075-1. Ganellin CR, Triggle JD, MacDonald F (1997). Dictionary of pharmacological agents - Google Books. CRC ...
Aaghaz S, Sharma K, Jain R, Kamal A (April 2021). "β-Carbolines as potential anticancer agents". European Journal of Medicinal ... November 2009). "Acute harmine administration induces antidepressive-like effects and increases BDNF levels in the rat ... August 2000). "Binding of beta-carbolines and related agents at serotonin (5-HT(2) and 5-HT(1A)), dopamine (D(2)) and ... they are also discussed as potential anticancer agents. The extract of the liana Banisteriopsis caapi has been used by the ...
PDE4 inhibitors may have antidepressive effects and have also been proposed for use as antipsychotics. On October 26, 2009, The ... The potential for selective phosphodiesterase inhibitors as therapeutic agents was predicted as early as 1977 by Weiss and Hait ... Recent studies have shown Quinazoline type PDE7 inhibitor to be potent anti-inflammatory and neuroprotective agents. ... Weiss B.; Hait W.N. (1977). "Selective cyclic nucleotide phosphodiesterase inhibitors as potential therapeutic agents". Annu. ...
It is thought that this is another key component of incensole's role as an anti-inflammatory agent. Incensole has also been ... anti-depressive, and sedative effects in mice. It is proposed that incensole works as an anti-inflammatory through the ...
Selectivity of antidepressant agents are based on the neurotransmitters that are thought to influence symptoms of depression. ... Venlafaxine was the first compound described in a new class of antidepressive substances called phenylethylamines. These ... Agents with dual serotonin and norepinephrine reuptake inhibition (SNRIs) are sometimes called non-tricyclic serotonin and ... It is recommended to washout 4 to 5 half-lives of the serotonergic agent before using an MAO inhibitor. Some studies suggest ...
Beresewicz M, Bidzińska E, Koszewska I, Puzyński S (1991). "[Results of using tricyclic antidepressive drugs in the treatment ... "Synthesis of Oxime Esters and Ethers as Potential Psychotropic Agents". Journal of Pharmaceutical Sciences. 54 (9): 1373-1376. ...
Thanawala V, Kadam VJ, Ghosh R (October 2008). "Enkephalinase inhibitors: potential agents for the management of pain". Curr ... In addition, opiorphin may exert anti-depressive and antipanic action. Therapeutic application of opiorphin in humans would ...
... 's antidepressive efficacy may predominantly result from its ability to desensitize 5-HT1A autoreceptors. Pindolol is a ... Celada P, Bortolozzi A, Artigas F (September 2013). "Serotonin 5-HT1A receptors as targets for agents to treat psychiatric ... Antihypertensive agents, Beta blockers, Indole ethers at the benzene ring, N-isopropyl-phenoxypropanolamines). ...
Triggle DJ (1996). Dictionary of Pharmacological Agents. Boca Raton: Chapman & Hall/CRC. p. 265. ISBN 978-0-412-46630-4. ... Moryl E, Danysz W, Quack G (June 1993). "Potential antidepressive properties of amantadine, memantine and bifemelane". ...
Earl DC, Van Tyle KM (November 2020). "New pharmacologic agents for insomnia and hypersomnia". Current Opinion in Pulmonary ... "Orexin/hypocretin receptor modulation of anxiolytic and antidepressive responses during social stress and decision-making: ...
The discovery of antidepressive action of ketamine in 2000 has been described as the single most important advance in the ... Sachdeva B, Sachdeva P, Ghosh S, Ahmad F, Sinha JK (March 2023). "Ketamine as a therapeutic agent in major depressive disorder ... Ketamine is an option in children, as the sole anesthetic for minor procedures or as an induction agent followed by ... It is also not clear whether ketamine alone is sufficient for the antidepressive action or its metabolites also are important. ...
The investigational agents seltorexant and vornorexant, which are still in clinical trials, have comparatively very short half- ... "Orexin/hypocretin receptor modulation of anxiolytic and antidepressive responses during social stress and decision-making: ... Roecker AJ, Cox CD, Coleman PJ (January 2016). "Orexin Receptor Antagonists: New Therapeutic Agents for the Treatment of ... January 2014). "Dual orexin receptor antagonists - promising agents in the treatment of sleep disorders". The International ...
Learn about Antidepressive Agents at online-medical-dictionary.org ... Antidepressive Agents. Synonyms. Agents, Antidepressive. Antidepressant Drugs. Antidepressants. Drugs, Antidepressant. ... The tricyclic compounds useful as antidepressive agents (ANTIDEPRESSIVE AGENTS, TRICYCLIC) also appear to act through brain ... A third group (ANTIDEPRESSIVE AGENTS, SECOND-GENERATION) is a diverse group of drugs including some that act specifically on ...
Antidepressive Agents, Tetracyclic. Accession Number. DBCAT003850. Description. Substances that contain a fused four-ring ...
"Antidepressive Agents, Second-Generation" by people in this website by year, and whether "Antidepressive Agents, Second- ... "Antidepressive Agents, Second-Generation" is a descriptor in the National Library of Medicines controlled vocabulary thesaurus ... Below are the most recent publications written about "Antidepressive Agents, Second-Generation" by people in Profiles. ... Below are MeSH descriptors whose meaning is more general than "Antidepressive Agents, Second-Generation". ...
This systematic review and meta-analysis highlighted a trend in favour of sertraline over other antidepressive agents both in ... Randomised controlled trials allocating patients with major depression to sertraline versus any other antidepressive agent. ... other SSRIs and newer agents in the acute-phase treatment of major depression. SEARCH STRATEGY: MEDLINE (1966 to 2008), EMBASE ... involving multiple treatment comparisons between sertraline and other antidepressant agents. Evidence favouring sertraline over ...
Antidepressive Agents / therapeutic use* * Case-Control Studies * Databases, Factual * Depression / drug therapy* ...
Lingjaerde O (November 1971). "[Imiprex "Dumex" (imipramine oxide). A new tricyclic antidepressive agent]". Tidsskrift for den ... preliminary investigation of a new antidepressive drug". The American Journal of Psychiatry. 120 (3): 277-8. doi:10.1176/ajp. ...
... a widely used anesthetic agent, is currently being investigated as a novel therapeutic for depression and suicidality. Ketamine ... Antidepressive Agents * Ketamine Grants and funding * K23 MH100259/MH/NIMH NIH HHS/United States ... Ketamine, a widely used anesthetic agent, is currently being investigated as a novel therapeutic for depression and suicidality ...
Agents producing tachycardia. *Agents that produce hypertension. *Anticonvulsants. *Antidepressive Agents. *BCRP/ABCG2 ...
... "antidepressive agents". Substituted Urea Derivatives: A Potent Class of Antidepressant Agents. Journal: Medicinal Chemistry. ... Antidepressants and Antipsychotic Agents as Repurposable Oncological Drug Candidates. Journal: Current Medicinal Chemistry. ... The State of the Art of Pyrazole Derivatives as Monoamine Oxidase Inhibitors and Antidepressant/Anticonvulsant Agents. Journal: ... Design Strategies, Chemistry and Therapeutic Insights of Multi-targetDirected Ligands as Antidepressant Agents. Journal: ...
Agomelatine versus other antidepressive agents for major depression. Cochrane Database of Systematic Reviews, ... Development of New Psychopharmacological Agents for Depression and Anxiety. Psychiatric Clinics of North America, Vol. 38, ... Doubt emerged regarding the value of agomelatine as a first-line agent when Novartis dropped the agomelatine development ...
Antidepressive Agents. 1. 2. Antifungal Agents. 2. 2. Immunomodulatory. 1. 2. Insulin Sensitizers. 1. 2. ... Pharmacological Actions : Anti-Inflammatory Agents, Hepatoprotective, Hypoglycemic Agents. Additional Keywords : Phytotherapy, ... Pharmacological Actions : Antineoplastic Agents, Antiproliferative , Apoptotic. Additional Keywords : Phytotherapy, Plant ... Pharmacological Actions : Enzyme Inhibitors, Gluconeogenesis Inhibitor, Hypoglycemic Agents. Additional Keywords : Plant ...
Pharmacological Actions : Antidepressive Agents, Gastrointestinal Agents. [+] Hesperidin-enriched orange juice could be a ... Pharmacological Actions : Gastrointestinal Agents, Hypoglycemic Agents, Hypolipidemic, Insulin Sensitizers. Additional Keywords ... Pharmacological Actions : Anti-Inflammatory Agents, Chemoprotective Agents, Interleukin-1 beta downregulation, Interleukin-6 ... Pharmacological Actions : Anti-Inflammatory Agents, Interleukin-6 Downregulation, MicroRNA modulator, NF-kappaB Inhibitor ...
Organic Compound; Amine; Drug; Adrenergic Uptake Inhibitor; Antidepressive Agent, Tricyclic; Antidepressant; Norepinephrine ...
Anti-Anxiety Agents/adverse effects/therapeutic use, Antidepressive Agents/adverse effects/therapeutic use, Humans, Randomized ... LR: 20140312; JID: 100909747; 0 (Anti-Anxiety Agents); 0 (Antidepressive Agents); UIN: Cochrane Database Syst Rev. 2014;1: ... Antifungal Agents/pharmacology, Biofilms/drug effects/growth & development, Candida/classification/drug effects/isolation & ...
Antidepressive Agents (Antidepressants) 8. Serotonin Uptake Inhibitors (Serotonin Reuptake Inhibitors) 9. Clomipramine ( ...
... classified as a mood-stabilizing agent. Lithium ion alters the metabolism of BIOGENIC MONOAMINES in the CENTRAL NERVOUS SYSTEM ... Antipsychotic Agents (Antipsychotics) 6. Antidepressive Agents (Antidepressants) 7. Propranolol (Inderal) 8. Indomethacin ( ... A lithium salt, classified as a mood-stabilizing agent. Lithium ion alters the metabolism of BIOGENIC MONOAMINES in the CENTRAL ...
keywords = "Antidepressive agents, Antipsychotic agents, ASEX, Depression, Psychopharmacology, Schizophrenia, Sexual ...
EMBASE:[{exp ANTIDEPRESSIVE AGENTS, TRICYCLIC OR tricyclic.mp. OR amitriptyline.mp. OR exp AMITRIPTYLINE OR desipramine.mp. OR ... Medline:[{exp ANTIDEPRESSIVE AGENTS, TRICYCLIC OR tricyclic.mp. OR amitriptyline.mp. OR exp AMITRIPTYLINE OR desipramine.mp. OR ...
Keywords: Acupuncture, Anti-N-Methyl-D-Aspartate Receptor Encephalitis, Acupuncture Therapy, Antidepressive Agents, Second- ... Finally, the PVDF membrane was reacted with freshly prepared enhanced chemiluminescent agent solution for 2 min, and the PVDF ...
Here the psychotropic agents include the antidepressive agents, hallucinogens, and tranquilizing agents (including the ...
keywords = "Antidepressive Agents, Tricyclic/therapeutic use, Double-Blind Method, Humans, Imipramine/therapeutic use, ...
5) Combination of an antidepressant with a neuroleptic agent also displaying certain antidepressive properties is really ... This is particularly important when the recommended agent is a new and/or infrequently employed drug. ...
Antidepressive Agents Medicine & Life Sciences 55% * Synaptic Potentials Medicine & Life Sciences 31% ...
Antidepressive Agents [D27.505.954.427.700.122] * Antidepressive Agents, Second-Generation [D27.505.954.427.700.122.050] ... Second-Generation Antidepressive Agents Registry Number. 0. Previous Indexing. Antidepressive Agents (1977-1994). Public MeSH ... Antidepressive Agents, Second-Generation Preferred Term Term UI T055641. Date01/01/1999. LexicalTag NON. ThesaurusID NLM (1995) ... Second-Generation Antidepressive Agents Term UI T055640. Date01/26/1994. LexicalTag NON. ThesaurusID NLM (1995). ...
... and the effects of serenics or antidepressive agents on both motivation and demotivation tend to have protean and unsuspected ... In short, agents agonistic at GABA receptors inhibit dopamine release. Agents which block opioid actions prevent disinhibition ...
OR exp Antidepressive Agents, Tricyclic/ OR ((TCA? and anti- depress$) or anti depress$) OR exp Stress Disorders, Traumatic/dt ... OR exp anti-anxiety agents/ or exp antipsychotic agents/ OR exp Anticonvulsants/ OR exp Serotonin Reuptake Inhibitors/ or exp ... or exp serotonin uptake inhibitors/ or exp serotonin agents/ or (selective serotonin reuptake inhibitors or SSRI?) OR exp ...
Antidepressive Agents. Katon WJ, Russo JE, Melville JL, Katon JG, Gavin AR. 2012. Depression in pregnancy is associated with ...
2012). Citalopram versus other anti-depressive agents for depression. PubMed Central (PMC). https://www.ncbi.nlm.nih.gov/pmc/ ...

No FAQ available that match "antidepressive agents"

No images available that match "antidepressive agents"